Literature DB >> 6625665

A study of the treatment of ovarian carcinoma.

H Pickel.   

Abstract

Between 1970 and early 1980, 213 patients were treated for ovarian carcinoma (stages Ib-IV) at the Department of Obstetrics and Gynecology, Graz University Medical School. Until mid 1976 patients were given postoperative radiotherapy; after that they were given combination chemotherapy (adriamycin and cyclophosphamide) according to Lloyd or Parker [18, 20, 21]. An analysis of the results led to the following conclusions: The operability at primary surgery is of prime importance, the best survival rates (regardless of postoperative management) being obtained in those patients in whom it is possible to do a pelvic clearance (removal of uterus, tubes and ovaries) with omentectomy. In patients who were operable postoperative chemotherapy was markedly superior to radiotherapy in terms of 1 year survival. But only slightly superior at 2 and 5 years. On the other hand, in patients who had palliative surgery postoperative radiotherapy seemed to give slightly better survival figures. Patients with early carcinoma (up to stage IIa) survived longer than those with late stages of carcinoma (IIb-IV) whether operable or not). The histology of the tumour had no discernible influence on the result both of chemotherapy and of radiotherapy. The patients with endometrioid and mucinous carcinomas had the highest survival rates irrespective of the postoperative treatment. However, the patients with serous cystadenocarcinomas survived longer than those with immature solid carcinomas. Patients who had no tumour at a second-look operation lived longer than those who had tumour at this time. Patients whose tumour recurred after the completion of postoperative radiotherapy and who were then given chemotherapy had the highest survival rates regardless of whether nor not the carcinoma was originally operable. It is felt that radiotherapy followed by chemotherapy should be used routinely especially in patients with late stages of ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6625665     DOI: 10.1007/bf02114598

Source DB:  PubMed          Journal:  Arch Gynecol        ISSN: 0170-9925


  17 in total

1.  Management of ovarian carcinoma. Current concepts and future prospects.

Authors:  J S Tobias; C T Griffiths
Journal:  N Engl J Med       Date:  1976-04-15       Impact factor: 91.245

2.  [Chemotherapy of malignant ovarian tumors].

Authors:  H Pickel; M Lahousen
Journal:  Wien Med Wochenschr       Date:  1977-09-30

3.  Radiation therapy for ovarian carcinoma.

Authors:  J R Eltringham
Journal:  Clin Obstet Gynecol       Date:  1979-12       Impact factor: 2.190

4.  [Chemotherapy of ovarian cancer].

Authors:  H Pickel; M Lahousen
Journal:  Gynakol Rundsch       Date:  1980-06

5.  Results of chemotherapy as an adjunct to surgery in patients with localized ovarian cancer.

Authors:  J P Smith; F N Rutledge; L Delclos
Journal:  Semin Oncol       Date:  1975-09       Impact factor: 4.929

6.  Postoperative treatment of early cancer of the ovary: a random trial between postoperative irradiation and chemotherapy.

Authors:  J P Smith; F N Rutledge; L Delclos
Journal:  Natl Cancer Inst Monogr       Date:  1975-10

7.  The role of adjuvant therapy in Stage I ovarian cancer.

Authors:  M M Hreshchyshyn; R C Park; J A Blessing; H J Norris; D Levy; L D Lagasse; W T Creasman
Journal:  Am J Obstet Gynecol       Date:  1980-09-15       Impact factor: 8.661

8.  Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer. A randomized clinical study.

Authors:  G Bolis; G Bortolozzi; G Carinelli; M D'Incalci; F Gramellini; L Morasca; C Mangioni
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

9.  Combination chemotherapy with adriamycin-cyclophosphamide for advanced ovarian carcinoma.

Authors:  L M Parker; C T Griffiths; R A Yankee; G P Canellos; R Gelman; R C Knapp; C M Richman; J S Tobias; R S Weiner; E Frei
Journal:  Cancer       Date:  1980-08-15       Impact factor: 6.860

10.  Surgery for common epithelial tumors of the ovary.

Authors:  J T Wharton; J Herson
Journal:  Cancer       Date:  1981-07-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.